Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$594.3m

Capricor Therapeutics Management

Management criteria checks 4/4

Capricor Therapeutics' CEO is Linda Marbán, appointed in Jan 2010, has a tenure of 14.92 years. total yearly compensation is $747.32K, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $2.61M. The average tenure of the management team and the board of directors is 12.8 years and 11.1 years respectively.

Key information

Linda Marbán

Chief executive officer

US$747.3k

Total compensation

CEO salary percentage29.5%
CEO tenure14.9yrs
CEO ownership0.4%
Management average tenure12.8yrs
Board average tenure11.1yrs

Recent management updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Recent updates

Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Dec 12
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Dec 06

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

CEO Compensation Analysis

How has Linda Marbán's remuneration changed compared to Capricor Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$747kUS$221k

-US$22m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$210k

-US$29m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$2mUS$200k

-US$20m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$150k

-US$14m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$229kUS$157k

-US$8m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$377kUS$233k

-US$15m

Sep 30 2018n/an/a

US$374k

Jun 30 2018n/an/a

US$2m

Mar 31 2018n/an/a

US$2m

Dec 31 2017US$602kUS$233k

US$2m

Compensation vs Market: Linda's total compensation ($USD747.32K) is below average for companies of similar size in the US market ($USD2.22M).

Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.

CEO

Linda Marbán (61 yo)

14.9yrs

Tenure

US$747,315

Compensation

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...

Leadership Team

NamePositionTenureCompensationOwnership
Frank Litvack
Executive Chairman of the Board12.9yrsUS$759.55k0.39%
$ 2.3m
Linda Marbán
Co-Founder14.9yrsUS$747.32k0.44%
$ 2.6m
Anthony Bergmann
CFO & Corporate Treasurer6.9yrsUS$730.85k0.0052%
$ 31.1k
Karen Krasney
Executive VP12.8yrsUS$740.77k0.062%
$ 366.6k
Kristi A. Elliott
Chief Science Officerno datano datano data
Catherine Kelleher
Consultantno datano datano data

12.8yrs

Average Tenure

64.5yo

Average Age

Experienced Management: CAPR's management team is seasoned and experienced (12.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frank Litvack
Executive Chairman of the Board12.9yrsUS$759.55k0.39%
$ 2.3m
Linda Marbán
Co-Founder11.1yrsUS$747.32k0.44%
$ 2.6m
George Dunbar
Independent Director11.1yrsUS$211.13k0.023%
$ 138.0k
Earl Collier
Independent Director11.1yrsUS$222.37k0.13%
$ 743.1k
David Musket
Independent Director11.1yrsUS$237.36k0.20%
$ 1.2m
Francesco Muntoni
Member of Scientific Advisory Boardno datano datano data
Pat Furlong
Member of Scientific Advisory Boardno datano datano data
Eugenio Mercuri
Member of Scientific Advisory Boardno datano datano data
Craig McDonald
Member of Scientific Advisory Boardno datano datano data
Oscar Mayer
Member of Scientific Advisory Boardno datano datano data
Michelle Eagle
Member of Scientific Advisory Boardno datano datano data
Michael Taylor
Member of Scientific Advisory Board6.9yrsno datano data

11.1yrs

Average Tenure

68yo

Average Age

Experienced Board: CAPR's board of directors are seasoned and experienced ( 11.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:29
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Capricor Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Reni BenjaminH.C. Wainwright & Co.
Joseph PantginisH.C. Wainwright & Co.